Notice of Change to Funding Opportunity for PAR-21-246, "HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)"
Notice Number:
NOT-TW-21-007

Key Dates

Release Date:

July 23, 2021

Related Announcements

PAR-21-246 - HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

Issued by

Fogarty International Center (FIC)

Purpose

The purpose of this Notice is to alert potential applicants of the following change to the Funding Opportunity Announcement (FOA), PAR-21-246 "HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)".

The following section of PAR-21-246 have been modified:

Currently Reads:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

In keeping with the suggested research topics above of interest to FIC, the following lists some specific focus areas of interest to the partner ICs in HIV-associated NCDs.

  • NIAMS is interested in observational, translational, and basic/pre-clinical research focusing on how the presence or treatment of HIV/AIDS impacts systemic rheumatic, musculoskeletal and skin disease progression and pathogenesis with a focus on utilization of existing HIV cohorts and repositories. NIAMS will not accept clinical trials under this FOA. Applicants who wish to submit clinical trial applications for consideration by NIAMS should submit to one of the NIAMS FOAs specifically for clinical trials at http://www.niams.nih.gov/Funding/Clinical_Research/clinical_main.asp.

  • NCI is interested in research projects aimed at identifying specific contributions of HIV infection and its potential interaction with other pathogens towards the development and pathogenesis of cancer, or provide information on the clinical outcomes in PLWH and cancer.

  • NIDDK is interested in basic, translational, clinical, and epidemiologic research on AIDS-related noncommunicable comorbidities within its mission. These include loss of gastrointestinal immune and microbial homeostasis, enteropathy and gastrointestinal diseases; liver diseases; kidney, urologic, and hematologic diseases; and metabolic perturbations, obesity, diabetes and associated complications

Proposed studies must be consistent with the NIH Office of AIDS Research priorities for HIV research (https://www.oar.nih.gov/hiv-policy-and-research/research-priorities;

https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html).

Modified to Read (changes shown in bold italics):

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

In keeping with the suggested research topics above of interest to FIC, the following lists some specific focus areas of interest to the partner ICs in HIV-associated NCDs.

  • NIAMS is interested in observational, translational, and basic/pre-clinical research focusing on how the presence or treatment of HIV/AIDS impacts systemic rheumatic, musculoskeletal and skin disease progression and pathogenesis with a focus on utilization of existing HIV cohorts and repositories. NIAMS will not accept clinical trials under this FOA. Applicants who wish to submit clinical trial applications for consideration by NIAMS should submit to one of the NIAMS FOAs specifically for clinical trials athttp://www.niams.nih.gov/Funding/Clinical_Research/clinical_main.asp.
  • NCI is interested in research projects aimed at identifying specific contributions of HIV infection and its potential interaction with other pathogens towards the development and pathogenesis of cancer, or provide information on the clinical outcomes in PLWH and cancer.
  • NIDA is interested in basic, translational, clinical and epidemiological research related to HIV-related noncommunicable comorbidities in the context of substance use disorders (SUD). Of specific interest are:
    • studies examining the role of drugs in pathogenesis of HIV-associated NCDs;
    • optimizing diagnosis and treatment strategies for NCDs in PLWH with SUDs;
    • develop and implement clinical strategies that improve long-term health outcomes for PLWH with SUDs;
    • research to explore new models of integrated care for SUD/NCD/HIV;
    • systems-level approaches to reducing stigma and barriers to accessing HIV and SUD prevention and treatment services, delivering patient-centered care for people with SUD and HIV, and increasing access to harm reduction services e.g. syringe service programs (SSP);
    • implementation research to evaluate integration of evidence-based prevention and care strategies for HIV and SUD at all levels of care delivery platforms with attention to sustainment facilitation.
  • NIDDK is interested in basic, translational, clinical, and epidemiologic research on AIDS-related noncommunicable comorbidities within its mission. These include loss of gastrointestinal immune and microbial homeostasis, enteropathy and gastrointestinal diseases; liver diseases; kidney, urologic, and hematologic diseases; and metabolic perturbations, obesity, diabetes and associated complications;

Proposed studies must be consistent with the NIH Office of AIDS Research priorities for HIV research (https://www.oar.nih.gov/hiv-policy-and-research/research-priorities;

https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html).

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Geetha P. Bansal, Ph.D.
Fogarty International Center
Telephone: 301-496-1492
Email: [email protected]


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices